4.22
Panoramica
Notizia
Cronologia dei prezzi
Perché EVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$4.20
Aprire:
$4.19
Volume 24 ore:
174.92K
Relative Volume:
1.27
Capitalizzazione di mercato:
$1.47B
Reddito:
$842.96M
Utile/perdita netta:
$-185.63M
Rapporto P/E:
-8.0243
EPS:
-0.5259
Flusso di cassa netto:
$-228.52M
1 W Prestazione:
+3.43%
1M Prestazione:
+6.30%
6M Prestazione:
+1.44%
1 anno Prestazione:
-13.17%
Evotec Se Adr Stock (EVO) Company Profile
Confronta EVO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
EVO
Evotec Se Adr
|
4.22 | 1.47B | 842.96M | -185.63M | -228.52M | -0.5259 |
![]()
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
![]()
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
2024-10-07 | Downgrade | Jefferies | Buy → Hold |
2024-08-08 | Downgrade | Deutsche Bank | Hold → Sell |
2024-07-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2024-07-11 | Downgrade | Deutsche Bank | Buy → Hold |
2024-04-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
2024-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2023-06-23 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2023-06-16 | Downgrade | BofA Securities | Buy → Neutral |
2023-06-08 | Aggiornamento | Citigroup | Neutral → Buy |
2023-04-04 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2022-12-09 | Iniziato | H.C. Wainwright | Buy |
2022-11-16 | Downgrade | Deutsche Bank | Buy → Hold |
2022-08-10 | Downgrade | Morgan Stanley | Overweight → Underweight |
2022-03-02 | Ripresa | Cowen | Outperform |
2022-01-07 | Ripresa | Citigroup | Neutral |
Mostra tutto
Evotec Se Adr Borsa (EVO) Ultime notizie
8 New 4-Star Stocks - Morningstar
Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister
Evotec SE (EVO) Stock Forecasts - Yahoo Finance
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria
Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Stock Information - Evotec
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com Australia
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks
Evotec: Management Streamlines Strategy to Refocus on Core Strengths Amid Biologics Momentum - Morningstar
Antibody Discovery Market Size to Achieve USD 22,570 Mn by 2034 | Statifacts - GlobeNewswire Inc.
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - BNN Bloomberg
Halozyme proposes $2 billion acquisition of Evotec - Investing.com
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Annual General Meeting - Evotec
Investor Relations - Evotec
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Healthcare Sector - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com
Evotec: Still A Speculative Buy After A Significant Decline (NASDAQ:EVO) - Seeking Alpha
Evotec SE ADR earnings, Revenue miss in Q3 By Investing.com - Investing.com India
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Together for Medicines That MatterEvotec - Evotec
Evotech and Roche subsidiary Genentech enter into drug discovery alliance - Proactive Investors USA
Evotec and Biogen Idec in research agreement - Proactive financial news
Evotec Se Adr Azioni (EVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):